A viral vector comprising sirt6 for treating a disease

EP4758259A1Pending Publication Date: 2026-06-17SIRT6 LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
SIRT6 LTD
Filing Date
2024-08-07
Publication Date
2026-06-17

AI Technical Summary

Technical Problem

Current therapeutic methods lack effective ways to increase SIRT6 expression for treating diseases and disorders, particularly in addressing age-related functional decline and neurodegenerative diseases.

Method used

A recombinant adeno-associated virus (rAAV) vector is developed, encoding a codon-optimized SIRT6 protein with customized stability and translation efficiency, and incorporating tissue-specific promoters and posttranscriptional regulatory elements to enhance expression and reduce immunogenicity.

Benefits of technology

The rAAV vector achieves efficient and controlled expression of SIRT6 in specific tissues, offering therapeutic potential for treating fibrotic conditions, metabolic disorders, neurodegenerative diseases, and other age-related diseases while minimizing safety risks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000046_0000
    Figure 00000046_0000
  • Figure 00000047_0000
    Figure 00000047_0000
  • Figure 00000047_0001
    Figure 00000047_0001
Patent Text Reader

Abstract

The invention concerns recombinant adeno-associated virus (rAAV) vectors comprising a polynucleotide sequence encoding a SIRT6 protein, wherein said polynucleotide sequence encoding a SIRT6 protein is codon-optimized for obtaining molecules with a customized stability, translation efficiency and / or reduced immunogenicity. As well as uses and methods employing the rAAV vectors for treating various diseases.
Need to check novelty before this filing date? Find Prior Art